Nintedanib for progressive fibrosing interstitial lung disease (PF-ILD) excluding idiopathic pulmonary fibrosis (IPF) [ID1599]

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	Kleijnen Systematic Reviews Ltd
Country	United Kingdom
Start Date	Jan 18, 2021
End Date	Jul 07, 2021
Duration	170 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133244`

Grant Description

To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating progressive fibrosing interstitial lung disease excluding idiopathic pulmonary fibrosis.